Peripartum cardiomyopathy
From Wikipedia, the free encyclopedia
| Peripartum cardiomyopathy Classification and external resources |
|
| ICD-9 | 674.5 |
|---|---|
| DiseasesDB | 29243 |
| eMedicine | med/292 |
Peripartum Cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting typically between the last month of pregnancy and up to five months postpartum. PPCM is a diagnosis of exclusion, wherein patients have no prior history of heart disease and there are no other causes of heart failure.9 Echocardiogram is used to both diagnose and monitor the effectiveness of treatment for PPCM.
As with other forms of dilated cardiomyopathy, PPCM involves a decrease of the left ventricular ejection fraction (EF) with associated congestive heart failure and an increased risk of atrial and ventricular arrhythmias and even sudden cardiac death.
The cause of PPCM is unknown.
Contents |
[edit] Prevalence
It is estimated that the incidence of PPCM in the United States is between 1 in 2000 to 4000 live births.5 While it inflicts women of all races, it is more prevalent in some countries; for example, estimates suggest that PPCM occurs at rates of one in 1000 live births in South African Bantus,12 and as high as one in 300 in Haiti.13 Some studies assert that PPCM may be slightly more prevalent among older women who have had higher numbers of liveborn children and among women of older and younger extremes of childbearing age.12, 14
However, a quarter to a third of PPCM patients are young women who have given birth for the first time.9, 11, 12, 13, 15, 16
While the use of tocolytic agents or the development of pre-eclempsia may contribute to the worsening of heart failure, they do not cause PPCM; many women have developed PPCM who neither received tocolytics nor had pre-eclempsia.11, 13
In short, PPCM can occur in any pregnancy.
Currently, researchers are investigating cardiotropic viruses, autoimmune dysfunction, and genetics as possible components that contribute to or cause the development of PPCM.7
[edit] Clinical Features
Symptoms usually include one or more of the following: orthopnea (difficulty breathing while lying flat), dyspnea (shortness of breath on exertion), pitting edema (swelling), cough, frequent night-time urination, excessive weight gain during the last month of pregnancy (two to four or more pounds per week), palpitations (sensation of racing heart-rate, skipping beats, long pauses between beats, or fluttering), and chest pain.4 The shortness of breath is often described by PPCM patients as the inability to take a deep or full breath or to get enough air into the lungs.
Unfortunately, patients and clinicians sometimes dismiss early symptoms because they appear to be typical of normal pregnancy. Yet, early detection and treatment are critically important to the patient with PPCM. Delays in diagnosis and treatment of PPCM are associated with increased morbidity and mortality.4
Occasionally patients present with other signs or symptoms. This is demonstrated by one report17 of a woman with liver failure five weeks postpartum who was being considered for liver transplant. An echocardiogram was performed and revealed PPCM and heart failure resulting in her severe liver failure. Conventional heart failure medications were administered. She survived and completely recovered from both the liver failure and PPCM.
For these reasons, it is paramount that clinicians hold a high suspicion of PPCM in any peri- or postpartum patient where unusual or unexplained symptoms or presentations occur.4, 17, 20
[edit] Prognosis
The most recent studies indicate that with newer conventional treatment, the survival rate is very high at 95% or better. 1,2,3 Most PPCM patients improve with treatment. World-wide, up to two-thirds (50-60%) of patients experience complete recovery of heart function (EF greater than 50%). Almost all recovered patients are eventually able to discontinue medications with no resulting relapse and have normal life expectancy.
It is a misconception that hope for recovery depends upon improvement or recovery within the first six to 12 months of diagnosis. Many women continue to improve or recover even years after diagnosis with continued medicinal treatment.4, 13
[edit] Treatment and Support
Early detection and treatment are associated with higher rates of recovery and decreased mortality.5
Treatment for PPCM is similar to treatment for congestive heart failure. Conventional heart failure treatment includes the use of diuretics, beta blockers (B-B), and angiotensin-converting enzyme inhibitors (ACE-I) after delivery or hydralzine/nitrates before delivery.4 If ACE-I is not well tolerated by the patient, it can be replaced by angio-tensin receptor blockers (ARB). Among B-B, carvedilol appears to provide the most advantages.
Diuretics help the body to get rid of excess water weight and also lower blood pressure. ACE-I and B-B improve blood circulation and contribute to the reversal of the immune system dysfunction associated with PPCM.
Sometimes implantation of a left ventricular assist device or even heart transplant also becomes necessary.18, 19
When recovery occurs quickly, it is still recommended that both ACE-I and B-B be continued for at least one year after diagnosis.4
Emotional as well as educational support may be helpful to the PPCM patient. The non-profit online organization, A Mother’s Heart, is dedicated to providing the most up-to-date medical information regarding PPCM as well as support from women around the world who share this disease. It is the largest online support group for PPCM world-wide and can be accessed at http://www.amothersheart.org/.
[edit] References
1. Felker GM, Jaeger CJ, Klodas E, Thiemann DR, Hare JM, Hruban RH, Kasper EK, Baughman KL. Myocarditis and long-term survival in peripartum cardiomyopathy. American Heart Journal 2000;140:785-91.
2. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary treatments. American Heart Journal 2006;152:509-13.
3. McNamara. Left ventricular recovery in peripartum cardiomyopathy: Impact of beta-blockade. Circulation 2007; 116, October 16, Supplement II, page 551, Abstract #2500.
4. Sliwa K, Fett JD, Elkayam U. Seminar: Peripartum cardiomyopathy. Lancet 2006; 368:687-93.
5. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, Ansari AA, Baughman KL. Peripartum cardiomyopathy. National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop recommendations and review. JAMA 2000; 283:1183-88.
6. Elkayam U, Padmini P, Tummala P, Rao K, Akhter MW, Karaalp IS, Wani OR, Hameed A, gviazda I, Shotan A. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. New England Journal Medicine 2001;344:1567-71.
7. Ansari AA, Fett JD, Carraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clinical Review Allergy Immunology 2002; 23:289-312.
8. Fett JD, Christie LG, Carraway RD, Sundstrom JB, Ansari AA, Murphy JG. Unrecognized peripartum cardiomyopathy in Haitian women. International Journal Gynaecology Obstetrics 2005; 90:161-6.
9. Elkayam U, Akhter MW, Singh HS, Khan S, Bitar F, Hameed A, Shotan A.Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111:2050-55.
10. Warraich RS, Fett JD, Damasceno A, Carraway RD, Sundrom JB, Arif J,Essop R, Ansari AA, Yacoub MH, Sliwa K. Impact of Pregnancy related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulinss in peripartum Cardiomyopathy. American Heart Journal 2005; 150:263-9.
11. Sliwa K, Forster O, Libhaber E, Fett J, Sundstrom JB, Hilfiker-Kleiner D,Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European Heart Journal. 2006; 27(4):441-6.
12. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Top Doct 1995; 25: 118-23.
13. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Proceed 2005; 80: 1602-06.
14. Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312: 1432-37.
15. Sliwa K, Skudicky D, Bergemann A, Cnady G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/Apo-1. J Am Coll Cardiol 2000; 35: 701-05.
16. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971: 44: 1053-60.
17. Fussell KM, Awad JA, Ware LB. Case of fulminant hepatic failure due to unrecognized peripartum cardiomyopathy. Crit Care Med 2005; 33: 891-93.
18. Phillips SD, Warnes CA. Peripartum cardiomyopathy: current therapeutic perspectives. Curr Treat Options Cardiovasc Med 2004; 6:481-88.
19. Aziz TM, Burgess MI, Acladious NN, et al. Heart transplantation for peripartum cardiomyopathy: a report of three cases and a literature review. Cardiovasc Surg 1999; 7:565-67.
20. Lasinska-Kowara, et al. Two cases of postpartum cardiomyopathy initially misdiagnosed for pulmonary embolism. Canadian J Anesthesia 2001; 48:773-777.
21. Fett JD, et al. Peripartum cardiomyopathy (PPCM) in both surrogate and biological mother. Human Reproduction 2005; 20:2666-2668.
|
||||||||||||||||||||||||||
